

Accepted Manuscript

Design, Synthesis and Structure–Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker

Jianyong Yang, Zheng Li, Huilan Li, Chunxia Liu, Nasi Wang, Wei Shi, Chen Liao, Xingguang Cai, Wenlong Huang, Hai Qian


PII: S0968-0896(17)30132-3
DOI: <http://dx.doi.org/10.1016/j.bmc.2017.03.001>
Reference: BMC 13596

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 21 January 2017
Revised Date: 9 February 2017
Accepted Date: 1 March 2017

Please cite this article as: Yang, J., Li, Z., Li, H., Liu, C., Wang, N., Shi, W., Liao, C., Cai, X., Huang, W., Qian, H., Design, Synthesis and Structure–Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker, *Bioorganic & Medicinal Chemistry* (2017), doi: <http://dx.doi.org/10.1016/j.bmc.2017.03.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Design, Synthesis and Structure–Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker

Jianyong Yang^{a,1}, Zheng Li^{a,1}, Huilan Li^a, Chunxia Liu^a, Nasi Wang^a, Wei Shi^a, Chen Liao^a, Xingguang Cai^a, Wenlong Huang^{a, b*}, Hai Qian^{a, b*}

^a Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.

^b Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.

Abstract

The free fatty acid receptor 1 (FFA1/GPR40) has attracted extensive attention as a novel antidiabetic target. Aiming to explore the chemical space of FFA1 agonists, a new series of lead compounds with amide linker were designed and synthesized by combining the scaffolds of NIH screened lead compound **1** and GW9508. Among them, the optimal lead compound **17** exhibited a considerable agonistic activity (45.78 %) compared to the NIH screened compound **1** (15.32 %). During OGTT in normal mice, the compound **17** revealed a significant glucose-lowering effect (-23.7 %) at the dose of 50 mg/kg, proximity to the hypoglycemic effect (-27.8 %) of Metformin (200 mg/kg). In addition, the compound **17** (100 mg/kg) also exhibited a significant improvement in glucose tolerance with a 29.1 % reduction of glucose AUC_{0-2h} in type 2 diabetic mice. All of these results indicated that compound **17** was considered to be a promising lead structure suitable for further optimization.

Keywords: Amide, FFA1 agonist, GPR40, Hybrid, Type 2 diabetes.

1. Introduction

* Co-corresponding authors: Wenlong Huang and Hai Qian, Centre of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Tel: +86-25-83271050; Fax: +86-25-83271050.

E-mail: ydhuangwenlong@126.com (W.L. Huang), qianhai24@163.com (H. Qian).

¹ These authors contributed equally to this work.

Download English Version:

<https://daneshyari.com/en/article/7775720>

Download Persian Version:

<https://daneshyari.com/article/7775720>

[Daneshyari.com](https://daneshyari.com)